429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma

by Antoni Ribas, Olivier Michielin, Reinhard Dummer, Scott Diede, Salvador Martin-Algarra, Sheryl Treichel, Edward Chan
Published 2020-11-01